Literature DB >> 17698824

Interaction between lopinavir/ritonavir and warfarin.

Christine A Hughes1, Andrea Freitas, Lilly J Miedzinski.   

Abstract

Drug interactions involving protease inhibitors are common. Protease inhibitors are well known inhibitors of the 3A4 isozyme of cytochrome P450. Select protease inhibitors, including co-formulated lopinavir/ritonavir, may induce glucuronidation or the activity of other CYP450 isozymes. We describe the case of a patient taking warfarin who experienced a significantly decreased international normalized ratio after the initiation of antiretroviral therapy that included lopinavir/ritonavir. We review the possible mechanisms of this interaction and the reported interactions between warfarin and other protease inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17698824      PMCID: PMC1942099          DOI: 10.1503/cmaj.061284

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  10 in total

1.  Ritonavir and warfarin interaction.

Authors:  G Newshan; P Tsang
Journal:  AIDS       Date:  1999-09-10       Impact factor: 4.177

2.  Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.

Authors:  Rosa F Yeh; Vincent E Gaver; Kristine B Patterson; Naser L Rezk; Faustina Baxter-Meheux; Michael J Blake; Joseph J Eron; Cheri E Klein; John C Rublein; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2006-05       Impact factor: 3.731

Review 3.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans.

Authors:  I Niopas; S Toon; L Aarons; M Rowland
Journal:  Eur J Clin Pharmacol       Date:  1999-07       Impact factor: 2.953

5.  Influence of indinavir and ritonavir on warfarin anticoagulant activity.

Authors:  G Gatti; A Alessandrini; M Camera; A Di Biagio; M Bassetti; F Rizzo
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

6.  Hypoprothrombinemia during concomitant therapy with warfarin and saquinavir.

Authors:  M R Darlington
Journal:  Ann Pharmacother       Date:  1997-05       Impact factor: 3.154

Review 7.  Systematic overview of warfarin and its drug and food interactions.

Authors:  Anne M Holbrook; Jennifer A Pereira; Renee Labiris; Heather McDonald; James D Douketis; Mark Crowther; Philip S Wells
Journal:  Arch Intern Med       Date:  2005-05-23

8.  Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction.

Authors:  Michael L Lim; Sherene S Min; Joseph J Eron; Richard J Bertz; Marjorie Robinson; Andrea Gaedigk; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2004-08-15       Impact factor: 3.731

9.  Potential interaction involving warfarin and ritonavir.

Authors:  K R Knoell; T M Young; E S Cousins
Journal:  Ann Pharmacother       Date:  1998-12       Impact factor: 3.154

Review 10.  Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Authors:  Risto S Cvetkovic; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  10 in total
  11 in total

1.  Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir.

Authors:  Brian J Kirby; Ann C Collier; Evan D Kharasch; Vaishali Dixit; Pankaj Desai; Dale Whittington; Kenneth E Thummel; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2011-09-19       Impact factor: 3.922

Review 2.  Managing drug interactions in HIV-infected adults with comorbid illness.

Authors:  Christine A Hughes; Alice Tseng; Ryan Cooper
Journal:  CMAJ       Date:  2014-09-15       Impact factor: 8.262

3.  A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.

Authors:  J B Dumond; M Vourvahis; N L Rezk; K B Patterson; H-C Tien; N White; S H Jennings; S O Choi; J Li; M J Wagner; N M La-Beck; M Drulak; J P Sabo; M A Castles; T R Macgregor; A D M Kashuba
Journal:  Clin Pharmacol Ther       Date:  2010-02-10       Impact factor: 6.875

Review 4.  Drug and dietary interactions of warfarin and novel oral anticoagulants: an update.

Authors:  Edith Nutescu; Ittiporn Chuatrisorn; Erika Hellenbart
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

5.  Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir.

Authors:  Brian J Kirby; Ann C Collier; Evan D Kharasch; Dale Whittington; Kenneth E Thummel; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2011-03-15       Impact factor: 3.922

6.  Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage.

Authors:  Lian Sheng Wang; Jing Jing Shang; Shu Ya Shi; Yan Qing Zhang; Jian Lin; Zhi Hua Guo; Yi Chen Wang; Jie Tang; Jie Liu; Ying Zi Liu; Zhi Li; Zhi Rong Tan; Hong Hao Zhou; Hai He Jiang; Hai Tang Xie
Journal:  Eur J Clin Pharmacol       Date:  2012-12-04       Impact factor: 2.953

7.  HIV-Associated Venous Thromboembolism.

Authors:  Michele Bibas; Gianluigi Biava; Andrea Antinori
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-07-08       Impact factor: 2.576

Review 8.  The challenge of HIV treatment in an era of polypharmacy.

Authors:  David Back; Catia Marzolini
Journal:  J Int AIDS Soc       Date:  2020-02       Impact factor: 5.396

Review 9.  Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications.

Authors:  Shubham Agarwal; Sanjeev Kumar Agarwal
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-12       Impact factor: 3.727

Review 10.  Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.

Authors:  Catherine Hodge; Fiona Marra; Catia Marzolini; Alison Boyle; Sara Gibbons; Marco Siccardi; David Burger; David Back; Saye Khoo
Journal:  J Antimicrob Chemother       Date:  2020-12-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.